TIDMCLIN

RNS Number : 0840J

Clinigen Group plc

18 December 2020

18 December 2020

Appointment of Nominated Adviser and Joint Broker

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global pharmaceutical and services company, has appointed Numis Securities Ltd as Nominated Adviser and Joint Broker with immediate effect. RBC Capital Markets will continue to act as the Group's Joint Broker.

-Ends-

Contact details

 
 Clinigen Group plc                                      Tel: +44 (0) 1283 495 
                                                                           010 
 Shaun Chilton, Group Chief Executive Officer 
  Nick Keher, Group Chief Financial Officer 
 
 Numis Securities Limited - Nominated Adviser             Tel: +44 (0) 20 7260 
  & Joint Broker                                                          1000 
 James Black / Freddie Barnfield / Garry 
  Levin 
 
                                                          Tel: +44 (0) 20 7653 
 RBC Capital Markets - Joint Broker                                       4000 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners                                      Tel: +44 (0) 20 7457 
                                                                          2020 
 Adrian Duffield / Melanie Toyne-Sewell 
  / Phillip Marriage                            Email: clinigen@instinctif.com

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

For more information on Clinigen, please visit www.clinigengroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPGPGQPPUPUGRM

(END) Dow Jones Newswires

December 18, 2020 02:00 ET (07:00 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Clinigen Charts.
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Clinigen Charts.